Niacin AIM HIGH study: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{Hyperlipidemia}} {{CMG}}; '''Associate Editor(s)-In-Chief:''' Priyamvada Singh, M.B.B.S. [mailto:psingh@perfuse.org] ==Overview== ==AIM HIGH study== * N..." |
No edit summary |
||
| Line 9: | Line 9: | ||
* Hypothesis - Whether raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels. | * Hypothesis - Whether raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels. | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
Revision as of 14:40, 20 November 2011
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
AIM HIGH study
- National Heart, Lung and Blood Institute (NHLBI) funded study.
- Hypothesis - Whether raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels.